Genetic counselling for hereditary predisposition to ovarian and breast cancer

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Mackay, J ^a   Szecsei, C M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

BCtect; BRCA1 2 testing; Clinical service development; CYP 2D6 genotyping; PARP inhibitors; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CYTOCHROME P450 2D6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BLOOD ANALYSIS; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CLINICAL PATHWAY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; EARLY DIAGNOSIS; FAMILY HISTORY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LINKAGE ANALYSIS; MAMMOGRAPHY; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; NATIONAL HEALTH SERVICE; NONHUMAN; OVARY CANCER; PENETRANCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TURNAROUND TIME; UNITED KINGDOM;

BREAST NEOPLASMS; CARCINOMA; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; OVARIAN NEOPLASMS;

EID: 78649366849     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq365     Document Type: Conference Paper

References (28)

1. Eccles DM, Evans DG, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). J Med Genet 2000; 37: 203-209.
2. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
3. Antoniou A, Pharoah PDP, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
4. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. Am J Hum Genet 2001; 68: 410-419.
5. Tischkowitz M, Mackay J. Inherited predisposition to cancer. In Cavalli F, Hansen H, Kaye S (eds): Textbook of Medical Oncology, 3rd edition. London: Martin Dunitz 2004; 413-426.
6. The FH01 Management Committee Steering Committee and Collaborators. The challenge of evaluating annual mammography screening for young women with a family history of breast cancer. J Med Screen 2006; 13: 177-182.
7. Lab21 Group. http://www.lab21.com/index.php (6 July 2010, date last accessed).
8. Myriad. http://www.myriad.com (6 July 2010, date last accessed).
9. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006; 34: 633-645.
10. Schreiber V, Dantzer F, Ame J-C, de Murcia G. Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528.
11. Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 2006; 6: 364-368.
12. Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.
13. Hay T. Matthews JR, Pietzka L et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69: 3850-3855.
14. Peter C, Fong MD, Boss DS et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
15. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115.
16. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093.
17. Mavaddat N, Dunning AM, Ponder BAJ et al. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol Biomarkers 2009; 18: 255-259.
18. Wu X, Hawse JR, Subramaniam M et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009; 69: 1722-1727.
19. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
20. Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74.
21. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.
22. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9: 576-586.
23. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693.
24. Aaroe J, Lindahl T, Dumeaux V et al. Gene expression profiling of peripheral blood cells for the early detection of breast cancer. Breast Cancer Res 2010; 12: R7.
25. Halle M. Blood test for breast cancer. Sunday Express (4 April 2010).
26. Martin D. Life saving blood test 'spots breast cancer early'. Daily Mail (5 April 2010).
27. Putlick H. New test for cancer offered in Scotland. The Herald (Glasgow 28 April 2010).
28. Diagenic. http://www.diagenic.com (6 July 2010, date last accessed).